Abasic (apurinic/apyrimidinic; AP) sites are generated in vivo through spontaneous base loss and by enzymatic removal of bases damaged by alkylating agents and reactive oxygen species. In Saccharomyces cerevisiae, the APN1 and APN2 genes function in alternate pathways of AP site removal. Apn2-like proteins have been identified in other eukaryotes including humans, and these proteins form a distinct subfamily within the exonuclease III (ExoIII)/Ape1/Apn2 family of proteins. Apn2 and other members of this subfamily contain a carboxyl-terminal extension not present in the ExoIII/ Ape1-like proteins. Here, we purify the Apn2 protein from yeast and show that it is a class II AP endonuclease. Deletion of the carboxyl terminus does not affect the AP endonuclease activity of the protein, but this protein is defective in the removal of AP sites in vivo. The carboxyl terminus may enable Apn2 to complex with other proteins, and such a multiprotein assembly may be necessary for the efficient recognition and cleavage of AP sites in vivo.Abasic (apurinic/apyrimidinic; AP) 1 sites are formed in DNA by spontaneous hydrolysis of the N-glycosylic bond and from the action of DNA glycosylases on modified bases. It has been estimated that a mammalian cell loses up to 10,000 purines per day from its genome (1). Class II AP endonucleases cleave the phosphodiester backbone on the 5Ј-side of the AP site and produce a 3Ј-OH group and a 5Ј-baseless deoxyribose 5Ј-phosphate residue. Removal of the 5Ј-abasic residue followed by DNA repair synthesis and ligation completes the repair process (2, 3).Two families of class II AP endonucleases have been identified in prokaryotes and eukaryotes. In Escherichia coli, exonuclease III (ExoIII) constitutes ϳ90% of the total AP endonuclease activity, and endonuclease IV represents about 10% of the total AP endonuclease (2, 3). In the yeast Saccharomyces cerevisiae, Apn1 and Apn2 are the respective homologs of E. coli endonuclease IV and ExoIII (4 -7). Apn1 and Apn2 represent alternate pathways for the repair of AP sites in yeast, since the apn1⌬ apn2⌬ double mutant strain displays a synergistic increase in sensitivity to the alkylating agent methyl methanesulfonate (MMS), and the repair of AP sites is severely impaired in this mutant (6). Consistent with the high mutagenicity of AP sites, the frequency of MMS-induced mutations is greatly elevated in the apn1⌬ apn2⌬ strain (6).Ape1, the human homolog of ExoIII, also known as Hap1, Apex, or Ref-1, is a class II AP endonuclease (8, 9). The yeast Apn2 protein is unique in that it possesses a C-terminal domain that is absent from the ExoIII/Ape1 proteins (6). Recently, a sequence, Ape2, has been identified in humans that possesses the C-terminal domain present in S. cerevisiae Apn2, and Ape2 also is more closely related to Apn2 than to ExoIII or Ape1. Thus, yeast Apn2 and its human counterpart, Ape2, represent a new subfamily in the ExoIII/Ape1/Apn2 family of proteins (see Fig. 1). Here, we purify the yeast Apn2 protein and show that it has an AP endonuclea...